Ovid is actively evaluating and forming partnerships and alliances with companies, clinicians, patient organizations and academic scientists.
Collaborations are core to the company’s strategy to expand and enhance its capabilities, as well as provide better medicines for patients.
For more information or inquiries on collaborations and partnerships, please contact email@example.com.
Developing BoldMedicine to Transform the Lives of People with Rare Neurological Disorders
In January 2017, Takeda and Ovid Therapeutics Inc. announced an innovative clinical development and commercialization collaboration for TAK-935/OV935 in rare pediatric epilepsies.
In April 2015, Lundbeck and Ovid Therapeutics Inc. announced an exclusive global licensing agreement for OV101.